High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Significance: Nanoparticle-mediated delivery of siRNA to hepatocytes has treated disease in humans. However, systemically delivering RNA drugs to nonliver tissues remains an important challenge. To increase the number of nanoparticles that could be studied in vivo, we designed a high-throughput method to measure how >100 nanoparticles delivered mRNA that was translated into functional protein in vivo. We quantified how >250 lipid nanoparticles (LNPs) delivered mRNA in vivo, identifying two LNPs that deliver mRNA to endothelial cells. One of the LNPs codelivered Cas9 mRNA and single-guide RNA in vivo, leading to endothelial cell gene editing. This approach can identify nanoparticles that target new cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Such assemblies, complexed with polymers capable of disrupting endosomes and including DNA templates for homology-directed repair, were found to promote correction of dystrophin gene mutations in mice 80 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
A robust and high-throughput Cre reporting and characterization system for the whole mouse brain
Madisen, L., Zwingman, T. A., Sunkin, S. M., Oh, S. W., Zariwala, H. A., Gu, H., Ng, L. L., Palmiter, R. D., Hawrylycz, M. J., Jones, A. R., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2467 · Cited by 6,907 · cited 2×
“LNPs that met these criteria were pooled together and administered to Lox-Stop-Lox-tdTomato (Ai14) mice (27).”
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
Zetsche, B., Gootenberg, J. S., Abudayyeh, O. O., Slaymaker, I. M., Makarova, K. S., Essletzbichler, P., Volz, S. E., Joung, J., van der Oost, J., Regev, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.038 · Cited by 4,761
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047 · cited 1×
“A lipid nanoparticle (LNP) siRNA therapy targeted to hepatocytes (1, 2) has been approved by the Food and Drug Administration (FDA).”
Easy quantitative assessment of genome editing by sequence trace decomposition
Brinkman, E. K., Chen, T., Amendola, M., & van Steensel, B. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku936 · Cited by 2,390 · cited 1×
“To confirm protein silencing was mediated by gene editing, we measured (40) ICAM-2 insertions and deletions (indels) in lung, spleen, and kidney endothelial cells and found between 30 and 70% editing per locus, leading to overall ICAM-2 indel percentages of 135, 95, and 123% indel, respectively for 7C2 (Fig.”
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001 · cited 6×
“Next, C57BL/6J mice were injected two times with 2 mg/kg with 7C3 formulated to carry both SpCas9 mRNA (L-7206; Trilink Biotechnology) and e-sgICAM2 (AxoLabs) at a 1:1, 3:1, and 5:1 mass ratio.”
InfluentialSelf-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“Moreover, LNP siRNA delivery is often tested in vivo using the FVII assay, which predicts hepatocyte delivery; this assay is enhanced by its ease, as well as the fact that validated, potent siRNA targeting FVII is available (18, 19).”
Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stöter, M., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2612 · Cited by 1,681
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., Joung, J. K., Chen, Z.-Y., & Liu, D. R. (2015) · Nature Biotechnology · doi:10.1038/nbt.3081 · Cited by 1,460 · cited 1×
“In mice, nanoparticles have delivered Cas9 mRNA and ribonu-cleoproteins via systemic or local injection (5 – 12).”
Cited by
Items 101–200 of 312
Universal Barcoding Predicts In Vivo ApoE-Independent Lipid Nanoparticle Delivery
Sanchez, A. J. D. S., Dobrowolski, C. N., Cristian, A., Echeverri, E. S., Zhao, K., Hatit, M. Z. C., Loughrey, D., Paunovska, K., & Dahlman, J. E. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01133 · Cited by 66
Self-citationTargeted delivery of RNAi to cancer cells using RNA-ligand displaying exosome
Uddin, N., Binzel, D. W., Shu, D., Fu, T., & Guo, P. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.11.019 · Cited by 65
CRISPR–Cas9 delivery strategies for the modulation of immune and non-immune cells
Alsaiari, S. K., Eshaghi, B., Du, B., Kanelli, M., Li, G., Wu, X., Zhang, L., Chaddah, M., Lau, A., Yang, X., et al. (2024) · Nature Reviews Materials · doi:10.1038/s41578-024-00725-7 · Cited by 70
Targeting materials and strategies for RNA delivery
Lin, L., Su, K., Cheng, Q., & Liu, S. (2023) · Theranostics · doi:10.7150/thno.87316 · Cited by 65
Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing
Fang, T., Cao, X., Ibnat, M., & Chen, G. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01570-y · Cited by 65
Lipid Nanoparticles for Nucleic Acid Delivery to Endothelial Cells
Liu, G. W., Guzman, E. B., Menon, N., & Langer, R. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03471-7 · Cited by 62
Dynamic carriers for therapeutic RNA delivery
Berger, S., Lächelt, U., & Wagner, E. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307799120 · Cited by 66
microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
Dong, J., He, M., Li, J., Pessentheiner, A., Wang, C., Zhang, J., Sun, Y., Wang, W.-T., Zhang, Y., Liu, J., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.143812 · Cited by 53
Thiophene-based lipids for mRNA delivery to pulmonary and retinal tissues
Eygeris, Y., Gupta, M., Kim, J., Jozić, A., Gautam, M., Renner, J., Nelson, D., Bloom, E., Tuttle, A., Stoddard, J., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307813120 · Cited by 62
Hamilton, A. G., Swingle, K. L., Thatte, A. S., Mukalel, A. J., Safford, H. C., Billingsley, M. M., El-Mayta, R. D., Han, X., Nachod, B. E., Joseph, R. A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01171 · Cited by 67
Targeting strategies for mRNA delivery
Meyer, R. A., Neshat, S. Y., Green, J. J., Santos, J. L., & Tuesca, A. D. (2022) · Materials Today Advances · doi:10.1016/j.mtadv.2022.100240 · Cited by 61
Substituting racemic ionizable lipids with stereopure ionizable lipids can increase mRNA delivery
Sanchez, A. J. D. S., Zhao, K., Huayamares, S. G., Hatit, M. Z. C., Lokugamage, M. P., Loughrey, D., Dobrowolski, C. N., Wang, S., Kim, H., Paunovska, K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.037 · Cited by 55
Self-citationIntelligent Biomaterialomics: Molecular Design, Manufacturing, and Biomedical Applications
Yi, Y., An, H., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202305099 · Cited by 53
Li, X., Li, J., Wei, J., Du, W., Su, C., Shen, X., Zhao, A., & Xu, M. (2025) · MedComm · doi:10.1002/mco2.70414 · Cited by 72
Modulating intracellular pathways to improve non-viral delivery of RNA therapeutics
de Vyver, T. V., Smedt, S. C. D., & Raemdonck, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114041 · Cited by 51
Hua, X., Han, K., Mandracchia, B., Radmand, A., Liu, W., Kim, H., Zhou, Y., Ehrlich, S. M., Li, K., Zheng, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46250-7 · Cited by 51
Self-citationLipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys
Kim, H., Zenhausern, R., Gentry, K., Lian, L., Huayamares, S. G., Radmand, A., Loughrey, D., Podilapu, A. R., Hatit, M. Z. C., Ni, H., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02470-2 · Cited by 72
Self-citationCell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles
Sago, C. D., Krupczak, B. R., Lokugamage, M. P., Gan, Z., & Dahlman, J. E. (2019) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-019-00573-4 · Cited by 60
Self-citationComprehensive analysis of lipid nanoparticle formulation and preparation for RNA delivery
Haque, M. A., Shrestha, A., Mikelis, C. M., & Mattheolabakis, G. (2024) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2024.100283 · Cited by 102
Delivery of RNAs to Specific Organs by Lipid Nanoparticles for Gene Therapy
Godbout, K., & Tremblay, J. P. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102129 · Cited by 53
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 56
Ashraf, M. U., Salman, H. M., Khalid, M. F., Khan, M. H. F., Anwar, S., Afzal, S., Idrees, M., & Chaudhary, S. U. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111239 · Cited by 49
On the mechanism of tissue-selective gene delivery by lipid nanoparticles
Kimura, S., & Harashima, H. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.03.052 · Cited by 49
Kim, J., Vaughan, H. J., Zamboni, C. G., Sunshine, J. C., & Green, J. J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.047 · Cited by 44
Incorporation of phosphatidylserine improves efficiency of lipid based gene delivery systems
Lotter, C., Alter, C. L., Bolten, J. S., Detampel, P., Palivan, C. G., Einfalt, T., & Huwyler, J. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.007 · Cited by 46
Delivery of CRISPR-Cas9 system for screening and editing RNA binding proteins in cancer
Yan, J., Kang, D. D., Turnbull, G., & Dong, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114042 · Cited by 46
Petersen, D. M. S., Weiss, R. M., Hajj, K. A., Yerneni, S. S., Chaudhary, N., Newby, A. N., Arral, M. L., & Whitehead, K. A. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400225 · Cited by 49
Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 52
Chan, C., Du, S., Dong, Y., & Cheng, X. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666201126162945 · Cited by 46
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 49
Lin, X., Liu, Y., Chemparathy, A., Pande, T., Russa, M. F. L., & Qi, L. S. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100245 · Cited by 46
Receptor–mediated transcytosis of macromolecules across the blood–brain barrier
Baghirov, H. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2255138 · Cited by 46
FASTAptameR 2.0: A web tool for combinatorial sequence selections
Kramer, S. T., Gruenke, P. R., Alam, K. K., Xu, D. H., & Burke, D. H. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.030 · Cited by 42
High-throughput platforms for machine learning-guided lipid nanoparticle design
Hanna, A. R., Issadore, D., & Mitchell, M. J. (2025) · Nature Reviews Materials · doi:10.1038/s41578-025-00831-0 · Cited by 58
Digital Barcodes for High-Throughput Screening
Yang, Z. R., Chen, J., Xiao, Y., Yang, C., Zhao, C., Chen, D., & Weitz, D. A. (2024) · Chem & Bio Engineering · doi:10.1021/cbe.3c00085 · Cited by 43
Enhanced target cell specificity and uptake of lipid nanoparticles using RNA aptamers and peptides
Ray, R. M., Hansen, A. H., Taskova, M., Jandl, B., Hansen, J. T., Soemardy, C., Morris, K. V., & Astakhova, K. (2021) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.17.75 · Cited by 41
Zheng, Q., Qin, F., Luo, R., Jin, C., Huang, H., He, X., Xiao, W., Guo, M., Yang, S., He, S., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202011068 · Cited by 40
Li, M., Li, S., Huang, Y., Chen, H., Zhang, S., Zhang, Z., Wu, W., Zeng, X., Zhou, B., & Li, B. (2021) · Advanced Materials · doi:10.1002/adma.202101707 · Cited by 43
High-throughput screening of nanoparticles in drug delivery
Tomé, I., Francisco, V., Fernandes, H., & Ferreira, L. (2021) · APL Bioengineering · doi:10.1063/5.0057204 · Cited by 41
Performance of nanoparticles for biomedical applications: The in vitro / in vivo discrepancy
Berger, S., Berger, M., Bantz, C., Maskos, M., & Wagner, E. (2022) · Biophysics Reviews · doi:10.1063/5.0073494 · Cited by 46
Alshehry, Y., Liu, X., Zhang, Y., & Zhu, G. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113617 · Cited by 39
Rational design of lipid nanoparticles for enabling gene therapies
Brimacombe, C. A., Kulkarni, J. A., Cheng, M. H. Y., An, K., Witzigmann, D., & Cullis, P. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101518 · Cited by 56
An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies
Das, A., Ahmed, R., Akhtar, S., Begum, K., & Banu, S. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101122 · Cited by 45
Badieyan, Z. S., & Evans, T. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0259 · Cited by 38
Biohybrid Nanoparticles to Negotiate with Biological Barriers
Mohammadi, M. R., Corbo, C., Molinaro, R., & Lakey, J. R. T. (2019) · Small · doi:10.1002/smll.201902333 · Cited by 38
On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes
Korablev, A. N., Lukyanchikova, V., Serova, I. A., & Баттулин, Н. Р. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103604 · Cited by 40
Jacobson, M. E., Becker, K. W., Palmer, C. R., Pastora, L. E., Fletcher, R. B., Collins, K. A., Fedorova, O., Duvall, C. L., Pyle, A. M., & Wilson, J. T. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00568 · Cited by 35
Advances in CRISPR Delivery Methods: Perspectives and Challenges
Demirci, S., Essawi, K., Germino-Watnick, P., Liu, X., Hakami, W., & Tisdale, J. F. (2022) · The CRISPR Journal · doi:10.1089/crispr.2022.0051 · Cited by 41
Byrnes, A. E., Dominguez, S. L., Yen, C.-W., Laufer, B. I., Foreman, O., Reichelt, M., Lin, H., Sagolla, M., Hötzel, K., Ngu, H., et al. (2023) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2023.05.005 · Cited by 38
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 40
A Polymeric Nanoparticle Formulation for Targeted mRNA Delivery to Fibroblasts
Rodrigues, A. F., Rebelo, C., Simões, S. M. N., Paulo, C., Pinho, S. L. C., Francisco, V., & Ferreira, L. (2022) · Advanced Science · doi:10.1002/advs.202205475 · Cited by 36
Non-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 38
Optimization of ionizable lipids for aerosolizable mRNA lipid nanoparticles
Lewis, M. M., Soto, M. R., Maier, E. Y., Wulfe, S., Bakheet, S., Obregon, H., & Ghosh, D. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10580 · Cited by 43
Li, S., Hu, Y., Lin, J., Schneiderman, Z., Shao, F., Wei, L., Li, A. I., Hsieh, K., Kokkoli, E., Curk, T., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c02341 · Cited by 47
He, M., Martin, M., Marin, T., Chen, Z. B., & Gongol, B. (2020) · APL Bioengineering · doi:10.1063/1.5129563 · Cited by 38
Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level
Kang, D. D., Marks, A. R., Morlà‐Folch, J., Dong, Y., Brown, B. D., & Teunissen, A. J. P. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01511-8 · Cited by 53
Spleen-targeted nanosystems for immunomodulation
Wang, F., Lou, J., Gao, X., Zhang, L., Sun, F., Wang, Z., Ji, T., & Qin, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101943 · Cited by 40
Design of efficacious somatic cell genome editing strategies for recessive and polygenic diseases
Carlson-Stevermer, J., Das, A., Abdeen, A. A., Fiflis, D., Grindel, B. I., Saxena, S., Akcan, T., Alam, T., Kletzien, H., Kohlenberg, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20065-8 · Cited by 32
Pre-clinical non-viral vectors exploited for in vivo CRISPR/Cas9 gene editing: an overview
Rouatbi, N., McGlynn, T., & Al‐Jamal, K. T. (2022) · Biomaterials Science · doi:10.1039/d1bm01452h · Cited by 37
Lee, S. M., Cheng, Q., Yu, X., Liu, S., Johnson, L. T., & Siegwart, D. J. (2020) · Angewandte Chemie · doi:10.1002/ange.202013927 · Cited by 36
mRNA-based modalities for infectious disease management
Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X., & Huang, Y. (2022) · Nano Research · doi:10.1007/s12274-022-4627-5 · Cited by 37
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 33
Next-generation materials for RNA–lipid nanoparticles: lyophilization and targeted transfection
Wang, T., Sung, T., Yu, T., Lin, H.-Y., Chen, Y.-H., Zhu, Z.-W., Gong, J., Pan, J., & Higuchi, A. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00308f · Cited by 37
Tailoring nanoparticles for targeted drug delivery: From organ to subcellular level
Liang, T., Xing, Z., Jiang, L., & Zhu, J. (2021) · Open Research (University of Surrey) · doi:10.1002/viw.20200131 · Cited by 31
Ryan, D. E., Diamant-Levi, T., Steinfeld, I., Taussig, D., Visal-Shah, S., Thakker, S., Lunstad, B. D., Kaiser, R. J., McCaffrey, R. M., Ortiz, M., et al. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00768 · Cited by 31
Design principles of lipid nanoparticles for RNA delivery
Arral, M. L., & Whitehead, K. A. (2026) · Nature Reviews Bioengineering · doi:10.1038/s44222-026-00401-1 · Cited by 57
Increased PIP3 activity blocks nanoparticle mRNA delivery
Paunovska, K., Sanchez, A. D. S., Foster, M. T., Loughrey, D., Blanchard, E. L., Islam, F. Z., Gan, Z., Mantalaris, A., Santangelo, P. J., & Dahlman, J. E. (2020) · Science Advances · doi:10.1126/sciadv.aba5672 · Cited by 26
Self-citationSmart Nucleic Acids as Future Therapeutics
Zhang, J., & Salaita, K. S. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.03.007 · Cited by 28
Davis, A. M., Morris, K. V., & Shevchenko, G. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.008 · Cited by 31
Yu, S.-Y., Carlaw, T., Thomson, T., Birkenshaw, A., Basha, G., Kurek, D. Z., Huang, C., Kulkarni, J. A., Zhang, L., & Ross, C. J. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.009 · Cited by 27
Theranostic Lipid Nanoparticles for Renal Cell Carcinoma
Mao, X., Wang, G., Wang, Z., Duan, C., Wu, X., & Xu, H. (2023) · Advanced Materials · doi:10.1002/adma.202306246 · Cited by 30
Li, Y., Li, R., Chakraborty, A., Ogurlu, R., Zhao, X., Chen, J., & Xu, Q. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00295 · Cited by 26
Prakash, S., Kumbhojkar, N., Clegg, J. R., & Mitragotri, S. (2020) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2020.101408 · Cited by 28
Recent advances in therapeutic CRISPR-Cas9 genome editing: mechanisms and applications
Zhou, L., & Yao, S. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00115-5 · Cited by 33
Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing
Zhang, H., Sun, R., Fei, J., Chen, H., & Lu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23115948 · Cited by 31
Barcoded screening identifies nanocarriers for protein delivery to kidney
Wang, L., Zhou, W., Chen, H., Jia, X., Zheng, P., Jiang, H., Wu, M., Zhang, Y., Ding, Y., Peng, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56257-3 · Cited by 32
Hanna, A. R., Shepherd, S. J., Datto, G., El-Mayta, R. D., Anderson, T., Navarro, I. B., Ricciardi, A. S., Padilla, M. S., Srikumar, N., Zhang, S., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c15613 · Cited by 27
Nonviral Delivery of CRISPR/Cas Systems in mRNA Format
Liu, Z., Li, Z., & Li, B. (2022) · Advanced NanoBiomed Research · doi:10.1002/anbr.202200082 · Cited by 28
Lipid nanoparticles deliver mRNA to the blood–brain barrier
Kuzminich, Y., Shakked, A., Calkins, R., Rudden, S., Jones, C., Doan, J., Jang, B., Echeverri, E. S., Zenhausern, R., Lian, L., et al. (2024) · Nano Research · doi:10.1007/s12274-024-6827-7 · Cited by 26
Self-citationLipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
Self-citationEfficient mRNA delivery using lipid nanoparticles modified with fusogenic coiled-coil peptides
Zeng, Y., Shen, M., Pattipeiluhu, R., Zhou, X., Zhang, Y., Bakkum, T., Sharp, T. H., Boyle, A. L., & Kros, A. (2023) · Nanoscale · doi:10.1039/d3nr02175k · Cited by 26
Programmable promoter editing for precise control of transgene expression
Kabaria, S. R., Bae, Y., Ehmann, M. E., Lende-Dorn, B. A., Beitz, A. M., Peterman, E. L., Love, K. S., Ploessl, D. S., & Galloway, K. E. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02854-y · Cited by 27
Multivalent Peptide-Functionalized Bioreducible Polymers for Cellular Delivery of Various RNAs
Yang, D., Eldredge, A. C., Hickey, J. C., Muradyan, H., & Guan, Z. (2020) · Biomacromolecules · doi:10.1021/acs.biomac.0c00211 · Cited by 23
Zamora, M. E., Omo‐Lamai, S., Patel, M. N., Wu, J., Arguiri, E., Vr, M., Myerson, J. W., Marcos-Contreras, O. A., & Brenner, J. S. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c05031 · Cited by 27
Lipid nanoparticle-mediated targeted mRNA delivery and its application in cancer therapy
Sui, Y., Hou, X., Zhang, J., Hong, X., Wang, H., Xiao, Y., & Zeng, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb01556a · Cited by 28
Synthetic RNA-based post-transcriptional expression control methods and genetic circuits
Pardi, M. L., Wu, J., Kawasaki, S., & Saito, H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114196 · Cited by 21
Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
Matsumura, T., Takano, T., & Takahashi, Y. (2022) · International Immunology · doi:10.1093/intimm/dxac064 · Cited by 24
Emerging lipid–polymer hybrid nanoparticles for genome editing
Gameiro, M. D., Mano, J. F., & Gaspar, V. M. (2024) · Polymer Chemistry · doi:10.1039/d4py00298a · Cited by 24
Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression
Zadory, M., Lopez, E., Babity, S., Gravel, S., & Brambilla, D. (2022) · Biomaterials Science · doi:10.1039/d2bm00859a · Cited by 18
Nanotechnology for organ-tunable gene editing
van der Meel, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0666-9 · Cited by 21
Non-Viral Targeted Nucleic Acid Delivery: Apply Sequences for Optimization
Wang, Y., & Wagner, E. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090888 · Cited by 20
Oh, C., Jung, H. S., Park, J., Awad, J., Jiang, D., Dowling, D. J., & Im, H. (2025) · ACS Nano · doi:10.1021/acsnano.5c04836 · Cited by 23
Targeting Strategies for Site-Specific mRNA Delivery
Di, J., Huang, P., & Chen, X. S. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00038 · Cited by 20
RNA–lipid nanoparticles for acute critical illnesses
Omo‐Lamai, S., Zamora, M. E., Mueller, B. K., Casciano, J. C., & Brenner, J. S. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00314-5 · Cited by 18
Exciting Times for Lipid Nanoparticles: How Canadian Discoveries Are Enabling Gene Therapies
Cheng, M. H. Y., Brimacombe, C. A., Verbeke, R., & Cullis, P. R. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00365 · Cited by 19
Tabrizi, E., & Li, B. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102609 · Cited by 24
mRNA Treatment Rescues Niemann–Pick Disease Type C1 in Patient Fibroblasts
Furtado, D. L., Cortez‐Jugo, C., Hung, Y. H., Bush, A. I., & Caruso, F. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00463 · Cited by 17
DNA-amphiphilic nanostructures: synthesis, characterization and applications
Jain, N., Singh, A., & Bhatia, D. D. (2025) · Nanoscale · doi:10.1039/d4nr03236e · Cited by 20
Type III CRISPR-based RNA editing for programmable control of SARS-CoV-2 and human coronaviruses
Lin, P., Shen, G., Guo, K., Qin, S., Pu, Q., Wang, Z., Gao, P., Xia, Z., Khan, M. N., Jiang, J., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac016 · Cited by 20
Glycolipid nanoparticles target the spleen and detarget the liver without charge
Gentry, K., Lian, L., Kim, H., Celik, O., Jones, C., Podilapu, A. R., Shakked, A., Loughrey, D., Zenhausern, R., Jang, B., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2409569122 · Cited by 18
Self-citation
Metadata
- Authors
- Sago, C. D., Lokugamage, M. P., Paunovska, K., Vanover, D. A., Monaco, C. M., Shah, N. N., Gamboa Castro, M., Anderson, S. E., Rudoltz, T. G., Lando, G. N., Munnilal Tiwari, P., Kirschman, J. L., Willett, N., Jang, Y. C., Santangelo, P. J., Bryksin, A. V., & Dahlman, J. E.
- Affiliations
- Georgia Institute of Technology (US)
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University School of Medicine, Atlanta, GA 30332;
- Corresponding author
- Dahlman, James E.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2018-10
- Volume
- 115
- Issue
- 42
- Pages
- E9944-E9952
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6196543
- OpenAlex
- W2893976143
- Cited by
- 313
- References
- 45
- Citations by year
- 2026: 37 · 2025: 45 · 2024: 46 · 2023: 44 · 2022: 58 · 2021: 31 · 2020: 36 · 2019: 16
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-11-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- HHS | National Institutes of Health (T32EB021962, T32GM008433, 5T32EB006343)
- Cystic Fibrosis Foundation (DAHLMA15XX0)
- Parkinson's Disease Foundation (PDF-JFA-1860)
- Bayer (AGE DTD)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- lipid nanoparticles, mRNA delivery, endothelial cells, CRISPR/Cas9 genome editing, siRNA delivery, single guide RNA, hepatocytes
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Animals, Cells, Cultured, Humans, Lipids, Mice, Inbred C57BL, RNA, Messenger, Gene Transfer Techniques, Hepatocytes, Endothelial Cells, Mice, Nanoparticles, High-Throughput Screening Assays, HEK293 Cells, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.